Solid Biosciences Inc (SLDB)

$5.62 -0.09 (-1.58%)
Market Cap 436.07M
Revenue (ttm) 0.00
Net Income (ttm) -124.70M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 366,583
Avg Vol 1,479,534
Day's Range N/A - N/A
Shares Out 77.87M
Stochastic %K 19%
Beta 2.44
Analysts Strong Sell
Price Target $15.42

Company Profile

Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It also develops SGT-212 for the treatment of Friedreich's ataxia that is in phase 1b clinical trial; SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia that is in preclinical phase; SGT-601 the treatment of TNNT2-mediated dilated cardiomyopath...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 337 4680
Address:
500 Rutherford Avenue, Third Floor, Charlestown, United States
Thr0winDarts
Thr0winDarts Aug. 27 at 5:21 PM
$SLDB hardest part of trading these small cap bios is the manipulation they undergo. This stock was systematically brought down from $10 in August 2024 to 2.80 in Feb 2025. Then, just like clockwork, it mysteriously starts increasing in volume for 5 days and moves from 2.80 to 4.20. It was as if the powers that be knew something was happening and covered their short position ahead of time. The following day data was released and it jumps to 7.20. Trading these companies where manipulation is so blatant and the playing field so uneven is very difficult. The reality now is data will be dumped again and the powers that be will know. Expect it to continue being run down and another spike in volume and price right before so they can cover their short position. It might not go under $3 again, but it likely will continue falling on low volume as long as nothing is announced.
0 · Reply
pharmd2828
pharmd2828 Aug. 27 at 4:58 PM
$SLDB some short sellers have covered per data dated 8/15! 1 m less short compared to 7/31/25! Cover b4 you shorts get crushed by coming tsunami …. Imho
0 · Reply
Thr0winDarts
Thr0winDarts Aug. 26 at 6:06 PM
$SLDB imagine we should be getting more data soon. Had 180 day data in Feb for two patients. Expect 360 day day to drop for them soon along with more 180 and 90 day data for newer participants
0 · Reply
pharmd2828
pharmd2828 Aug. 26 at 4:59 PM
$SLDB she is sitting on a lunch pad imho !!
0 · Reply
Thr0winDarts
Thr0winDarts Aug. 25 at 7:20 PM
$SLDB pretty impressive how they can walk it down on such low volume. Shows how awful liquitity is for the stock.
0 · Reply
Bio_Invest101
Bio_Invest101 Aug. 25 at 2:26 AM
$IRWD A Short clip but worth of the retails to remember what roles we play in the whole game. BLTA https://stocktwits.com/Bio_Invest101/message/626386428 $DAWN $SLDB
0 · Reply
Impatient_Investor
Impatient_Investor Aug. 21 at 6:41 AM
$SLDB pump and dump garbage
0 · Reply
BluntForceOptions
BluntForceOptions Aug. 20 at 3:15 PM
$SLDB Fib. & Chart Update: As flagged in my earlier post (Aug 4), weakness was expected absent fresh catalysts. The chart is now sitting around the 0.382 Fib retrace (~$5.45) -- a key support zone, IMO. If this level doesn’t hold, the next downside marker lines up near the 0.236 (~$4.29). On the flip side, stabilization here would keep the prior breakout structure intact. Nothing’s changed on the fundamental side since ER, so price action is doing the heavy lifting. And with the broader market showing signs of rolling over, sellers may press harder if this level cracks. This is the spot where the tape either finds footing or breaks lower into the next leg. Stay tuned and GLTA.
0 · Reply
GammaRadiated
GammaRadiated Aug. 20 at 2:36 PM
$SLDB anyone have a clue why this stock has dropped so much in two weeks?
0 · Reply
jposmak
jposmak Aug. 20 at 2:18 PM
$SLDB nothing wrong with the paper dont be foolish on those time
0 · Reply
Latest News on SLDB
Solid Biosciences Reports Second Quarter 2025 Financial Results and Provides Business Updates

Aug 12, 2025, 4:07 PM EDT - 15 days ago

Solid Biosciences Reports Second Quarter 2025 Financial Results and Provides Business Updates

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aug 1, 2025, 8:00 AM EDT - 26 days ago

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Solid Biosciences Receives FDA Fast Track Designation for SGT-501 First-in-Class Gene Therapy for Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

Jul 23, 2025, 8:00 AM EDT - 5 weeks ago

Solid Biosciences Receives FDA Fast Track Designation for SGT-501 First-in-Class Gene Therapy for Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

Solid Biosciences: SGT-003's Safety Profile Illuminates DMD Gene Therapy Path (Rating Upgrade)

Jul 11, 2025, 3:02 PM EDT - 6 weeks ago

Solid Biosciences: SGT-003's Safety Profile Illuminates DMD Gene Therapy Path (Rating Upgrade)

SHAREHOLDER NOTICE: Kaskela Law LLC Announces Shareholder Investigation of Solid Biosciences Inc. (NASDAQ: SLDB) and Encourages Long-Term SLDB Investors to Contact the Firm

Jul 10, 2025, 8:00 AM EDT - 6 weeks ago

SHAREHOLDER NOTICE: Kaskela Law LLC Announces Shareholder Investigation of Solid Biosciences Inc. (NASDAQ: SLDB) and Encourages Long-Term SLDB Investors to Contact the Firm

Solid Biosciences Announces FDA IND and Health Canada CTA Approval for First-in-Class Cardiac Gene Therapy to Treat Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

Jul 8, 2025, 4:05 PM EDT - 7 weeks ago

Solid Biosciences Announces FDA IND and Health Canada CTA Approval for First-in-Class Cardiac Gene Therapy to Treat Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

Solid Biosciences to Participate at the Jefferies Global Healthcare Conference

May 28, 2025, 8:00 AM EDT - 3 months ago

Solid Biosciences to Participate at the Jefferies Global Healthcare Conference

Solid Biosciences Reports First Quarter 2025 Financial Results and Provides Business Updates

May 15, 2025, 4:06 PM EDT - 3 months ago

Solid Biosciences Reports First Quarter 2025 Financial Results and Provides Business Updates

Solid Biosciences to Participate at The Citizens Life Sciences Conference

Apr 30, 2025, 8:00 AM EDT - 4 months ago

Solid Biosciences to Participate at The Citizens Life Sciences Conference

Solid Biosciences to Present at the American Society of Gene and Cell Therapy's 28th Annual Meeting

Apr 29, 2025, 8:00 AM EDT - 4 months ago

Solid Biosciences to Present at the American Society of Gene and Cell Therapy's 28th Annual Meeting

Solid Biosciences: A Strong Buy As An Emerging Biotech In The Gene Therapy Space

Apr 8, 2025, 4:50 PM EDT - 5 months ago

Solid Biosciences: A Strong Buy As An Emerging Biotech In The Gene Therapy Space

Drug stocks sink as FDA's top vaccine official is ousted in Trump overhaul

Mar 31, 2025, 2:25 PM EDT - 5 months ago

Drug stocks sink as FDA's top vaccine official is ousted in Trump overhaul

BNTX NVAX SRPT TSHA XBI

Solid Biosciences to Present at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Mar 12, 2025, 8:00 AM EDT - 6 months ago

Solid Biosciences to Present at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Solid Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Mar 6, 2025, 4:16 PM EST - 6 months ago

Solid Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Solid Biosciences to Participate at Upcoming Investor Conferences

Mar 5, 2025, 8:00 AM EST - 6 months ago

Solid Biosciences to Participate at Upcoming Investor Conferences

Solid Biosciences Stock Surges On Upbeat Duchenne Muscular Dystrophy Gene Therapy Data

Feb 18, 2025, 12:29 PM EST - 6 months ago

Solid Biosciences Stock Surges On Upbeat Duchenne Muscular Dystrophy Gene Therapy Data

Solid Biosciences Announces Pricing of Underwritten Offering

Feb 18, 2025, 7:00 AM EST - 6 months ago

Solid Biosciences Announces Pricing of Underwritten Offering

Solid Biosciences Reports Positive Initial Clinical Data from Next-Generation Duchenne Gene Therapy Candidate SGT-003

Feb 18, 2025, 6:45 AM EST - 6 months ago

Solid Biosciences Reports Positive Initial Clinical Data from Next-Generation Duchenne Gene Therapy Candidate SGT-003

Solid Biosciences: Differentiating Factors Of SGT-212 To Set Itself Apart

Jan 21, 2025, 6:27 PM EST - 7 months ago

Solid Biosciences: Differentiating Factors Of SGT-212 To Set Itself Apart

Solid Biosciences Receives FDA Fast Track Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich's Ataxia

Jan 21, 2025, 8:30 AM EST - 7 months ago

Solid Biosciences Receives FDA Fast Track Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich's Ataxia

Solid Biosciences Outlines Key Priorities for Advancing Diversified Neuromuscular and Cardiac Development Pipeline and Establishing Leadership in Precision Genetic Medicines

Jan 15, 2025, 4:05 PM EST - 7 months ago

Solid Biosciences Outlines Key Priorities for Advancing Diversified Neuromuscular and Cardiac Development Pipeline and Establishing Leadership in Precision Genetic Medicines

Solid Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 8, 2025, 4:05 PM EST - 8 months ago

Solid Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Solid Biosciences Announces FDA IND Clearance for First-In-Industry Dual Route of Administration Gene Therapy to Treat Both Neurologic and Cardiac Manifestations of Friedreich's Ataxia

Jan 7, 2025, 4:15 PM EST - 8 months ago

Solid Biosciences Announces FDA IND Clearance for First-In-Industry Dual Route of Administration Gene Therapy to Treat Both Neurologic and Cardiac Manifestations of Friedreich's Ataxia

Solid Biosciences Added to the Nasdaq Biotechnology Index

Dec 23, 2024, 4:05 PM EST - 8 months ago

Solid Biosciences Added to the Nasdaq Biotechnology Index

Solid Biosciences Positioned For Next-Gen Duchenne Muscular Dystrophy Treatment Success: Analyst

Dec 13, 2024, 1:52 PM EST - 9 months ago

Solid Biosciences Positioned For Next-Gen Duchenne Muscular Dystrophy Treatment Success: Analyst

Solid Biosciences to Present at the Jefferies London Healthcare Conference

Nov 14, 2024, 8:00 AM EST - 10 months ago

Solid Biosciences to Present at the Jefferies London Healthcare Conference

Solid Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Updates

Nov 6, 2024, 4:05 PM EST - 10 months ago

Solid Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Updates

Solid Biosciences to Participate at the 2024 Cantor Global Healthcare Conference

Sep 12, 2024, 8:00 AM EDT - 1 year ago

Solid Biosciences to Participate at the 2024 Cantor Global Healthcare Conference

Solid Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Updates

Aug 13, 2024, 4:08 PM EDT - 1 year ago

Solid Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Updates

Solid Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jul 1, 2024, 4:19 PM EDT - 1 year ago

Solid Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Solid Biosciences Provides First Quarter 2024 Business Update and Financial Results

May 15, 2024, 7:52 AM EDT - 1 year ago

Solid Biosciences Provides First Quarter 2024 Business Update and Financial Results

Buy Solid Biosciences: Unpacking Its Main Value Driver

Apr 10, 2024, 7:32 PM EDT - 1 year ago

Buy Solid Biosciences: Unpacking Its Main Value Driver

Solid Biosciences Receives Rare Pediatric Disease Designation from the FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003

Apr 1, 2024, 7:45 AM EDT - 1 year ago

Solid Biosciences Receives Rare Pediatric Disease Designation from the FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003

Solid Biosciences Provides Fourth Quarter and Full-Year 2023 Business Update and Financial Results

Mar 13, 2024, 7:44 AM EDT - 1 year ago

Solid Biosciences Provides Fourth Quarter and Full-Year 2023 Business Update and Financial Results

Solid Biosciences: DMD Treatment Advancement With Next-Generation Capsid

Jan 16, 2024, 11:01 PM EST - 1 year ago

Solid Biosciences: DMD Treatment Advancement With Next-Generation Capsid

Solid Biosciences Granted FDA Orphan Drug Designation for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003

Jan 16, 2024, 8:00 AM EST - 1 year ago

Solid Biosciences Granted FDA Orphan Drug Designation for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003

Solid Biosciences Announces $109 Million Private Placement

Jan 8, 2024, 7:09 AM EST - 1 year ago

Solid Biosciences Announces $109 Million Private Placement

Solid Biosciences to Participate at 35th Annual Piper Sandler Healthcare Conference

Nov 22, 2023, 8:00 AM EST - 1 year ago

Solid Biosciences to Participate at 35th Annual Piper Sandler Healthcare Conference

Solid Biosciences Provides Third Quarter Business Update and Financial Results

Nov 8, 2023, 4:17 PM EST - 1 year ago

Solid Biosciences Provides Third Quarter Business Update and Financial Results

Solid Biosciences Appoints Gabriel Brooks, M.D., as Chief Medical Officer

Oct 2, 2023, 8:00 AM EDT - 2 years ago

Solid Biosciences Appoints Gabriel Brooks, M.D., as Chief Medical Officer

Solid Biosciences Provides Second Quarter Business Update and Financial Results

Aug 14, 2023, 4:17 PM EDT - 2 years ago

Solid Biosciences Provides Second Quarter Business Update and Financial Results

Solid Biosciences to Participate at the Jefferies Healthcare Conference

Jun 1, 2023, 8:00 AM EDT - 2 years ago

Solid Biosciences to Participate at the Jefferies Healthcare Conference

Solid Biosciences to Participate at the Barclays Gene Editing & Therapy Summit

May 22, 2023, 8:00 AM EDT - 2 years ago

Solid Biosciences to Participate at the Barclays Gene Editing & Therapy Summit

Solid Biosciences to Present at the American Society of Gene and Cell Therapy Annual Meeting

May 16, 2023, 8:00 AM EDT - 2 years ago

Solid Biosciences to Present at the American Society of Gene and Cell Therapy Annual Meeting

Solid Biosciences Provides First Quarter Business Update and Financial Results

May 11, 2023, 7:30 AM EDT - 2 years ago

Solid Biosciences Provides First Quarter Business Update and Financial Results

Solid Biosciences to Present at JMP Securities Life Sciences Conference

May 8, 2023, 4:05 PM EDT - 2 years ago

Solid Biosciences to Present at JMP Securities Life Sciences Conference

Solid Biosciences to Participate in Chardan's 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

Apr 21, 2023, 8:00 AM EDT - 2 years ago

Solid Biosciences to Participate in Chardan's 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

Solid Biosciences to Present at the 22nd Annual Needham Healthcare Conference

Apr 13, 2023, 8:00 AM EDT - 2 years ago

Solid Biosciences to Present at the 22nd Annual Needham Healthcare Conference

Solid Biosciences Provides Fourth Quarter and Full-Year 2022 Business Update and Financial Results

Mar 23, 2023, 8:00 AM EDT - 2 years ago

Solid Biosciences Provides Fourth Quarter and Full-Year 2022 Business Update and Financial Results

Solid Biosciences to Participate at BMO Biopharma Spotlight Series: Genetic Medicine Delivery

Mar 21, 2023, 8:00 AM EDT - 2 years ago

Solid Biosciences to Participate at BMO Biopharma Spotlight Series: Genetic Medicine Delivery

Thr0winDarts
Thr0winDarts Aug. 27 at 5:21 PM
$SLDB hardest part of trading these small cap bios is the manipulation they undergo. This stock was systematically brought down from $10 in August 2024 to 2.80 in Feb 2025. Then, just like clockwork, it mysteriously starts increasing in volume for 5 days and moves from 2.80 to 4.20. It was as if the powers that be knew something was happening and covered their short position ahead of time. The following day data was released and it jumps to 7.20. Trading these companies where manipulation is so blatant and the playing field so uneven is very difficult. The reality now is data will be dumped again and the powers that be will know. Expect it to continue being run down and another spike in volume and price right before so they can cover their short position. It might not go under $3 again, but it likely will continue falling on low volume as long as nothing is announced.
0 · Reply
pharmd2828
pharmd2828 Aug. 27 at 4:58 PM
$SLDB some short sellers have covered per data dated 8/15! 1 m less short compared to 7/31/25! Cover b4 you shorts get crushed by coming tsunami …. Imho
0 · Reply
Thr0winDarts
Thr0winDarts Aug. 26 at 6:06 PM
$SLDB imagine we should be getting more data soon. Had 180 day data in Feb for two patients. Expect 360 day day to drop for them soon along with more 180 and 90 day data for newer participants
0 · Reply
pharmd2828
pharmd2828 Aug. 26 at 4:59 PM
$SLDB she is sitting on a lunch pad imho !!
0 · Reply
Thr0winDarts
Thr0winDarts Aug. 25 at 7:20 PM
$SLDB pretty impressive how they can walk it down on such low volume. Shows how awful liquitity is for the stock.
0 · Reply
Bio_Invest101
Bio_Invest101 Aug. 25 at 2:26 AM
$IRWD A Short clip but worth of the retails to remember what roles we play in the whole game. BLTA https://stocktwits.com/Bio_Invest101/message/626386428 $DAWN $SLDB
0 · Reply
Impatient_Investor
Impatient_Investor Aug. 21 at 6:41 AM
$SLDB pump and dump garbage
0 · Reply
BluntForceOptions
BluntForceOptions Aug. 20 at 3:15 PM
$SLDB Fib. & Chart Update: As flagged in my earlier post (Aug 4), weakness was expected absent fresh catalysts. The chart is now sitting around the 0.382 Fib retrace (~$5.45) -- a key support zone, IMO. If this level doesn’t hold, the next downside marker lines up near the 0.236 (~$4.29). On the flip side, stabilization here would keep the prior breakout structure intact. Nothing’s changed on the fundamental side since ER, so price action is doing the heavy lifting. And with the broader market showing signs of rolling over, sellers may press harder if this level cracks. This is the spot where the tape either finds footing or breaks lower into the next leg. Stay tuned and GLTA.
0 · Reply
GammaRadiated
GammaRadiated Aug. 20 at 2:36 PM
$SLDB anyone have a clue why this stock has dropped so much in two weeks?
0 · Reply
jposmak
jposmak Aug. 20 at 2:18 PM
$SLDB nothing wrong with the paper dont be foolish on those time
0 · Reply
Bio_Invest101
Bio_Invest101 Aug. 19 at 3:59 PM
$SLDB FA CRL and Regenxbio's Hunter syndrome gene therapy delay https://www.fiercebiotech.com/biotech/ptc-therapeutics-friedreichs-ataxia-hopes-derailed-crl-fda
1 · Reply
chop14
chop14 Aug. 18 at 8:23 PM
$SLDB insiders buying ? $SRPT
0 · Reply
iQuicky
iQuicky Aug. 15 at 4:11 PM
$SLDB it’s okay to take a break
0 · Reply
Bio_Invest101
Bio_Invest101 Aug. 15 at 3:02 PM
$CAPR “Randomized trials are not always needed to approve medical products and this approval is proof of that philosophy,” Vinay Prasad, M.D., the director of the FDA’s Center for Biologics Evaluation and Research, said in a release. “The FDA will always demand the correct clinical study for the specific medical product and disease. Our requirements for products given to tens of millions of healthy people will be different than products given to at most hundreds or thousands of patients with unique diseases.” $SLDB https://www.fiercepharma.com/pharma/precigen-scores-fda-nod-first-ever-treatment-hpv-related-disorder
1 · Reply
pharmd2828
pharmd2828 Aug. 15 at 3:00 AM
$SLDB RA capital now owns 8m shares of SLDB per new filing! Very bullish imho
0 · Reply
Bio_Invest101
Bio_Invest101 Aug. 15 at 12:03 AM
$SLDB Surprise ! 2025-08-14 - Commodore Capital Lp has filed an SCHEDULE 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 0 shares of Solid Biosciences Inc. (US:SLDB). This represents 0.0 percent ownership of the company. In their previous filing dated 2025-02-25 , Commodore Capital Lp had reported owning 5,825,000 shares, indicating a decrease of -100.00 percent.
0 · Reply
Bio_Invest101
Bio_Invest101 Aug. 15 at 12:02 AM
$SLDB Ra Capital Management comes back 2025-08-14 - Ra Capital Management, L.p. has filed an SCHEDULE 13D/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 7,997,510 shares of Solid Biosciences Inc. (US:SLDB). This represents 9.9 percent ownership of the company.
0 · Reply
pharmd2828
pharmd2828 Aug. 14 at 10:57 PM
$SLDB institutional coverage shows 109.5%!!! jumped 5% yesterday ! is it because institutions are really buying more or they’re shorting the stock!! or discrepancies in reporting late !!
0 · Reply
JarvisFlow
JarvisFlow Aug. 14 at 3:49 PM
JP Morgan has updated their rating for Solid Biosciences ( $SLDB ) to Overweight with a price target of 13.
0 · Reply
Bio_Invest101
Bio_Invest101 Aug. 14 at 12:19 PM
$SLDB Holding strong On August 13, 2025 - Siren, L.L.C. filed a 13F-HR form disclosing ownership of 7,415,905 shares of Solid Biosciences Inc. (US:SLDB) valued at $36,115,457 USD as of June 30, 2025. The entity filed a previous 13F-HR/A on May 23, 2025 disclosing 7,415,905 shares of Solid Biosciences Inc.. This represents a change in shares of 0.00% during the quarter. The current value of the position is $49,538,245 USD. On August 14, 2025 - State Street Corp filed a 13F-HR form disclosing ownership of 951,452 shares of Solid Biosciences Inc. (US:SLDB) valued at $4,633,571 USD as of June 30, 2025. The entity filed a previous 13F-HR on May 15, 2025 disclosing 436,276 shares of Solid Biosciences Inc.. This represents a change in shares of 118.08% during the quarter. The current value of the position is $6,355,699 USD.
0 · Reply
pharmd2828
pharmd2828 Aug. 13 at 11:14 PM
$SLDB updates; Good price action today post Earnings! Earnings gave many investors a sense of confidence in SLDB management! - 15 pts dosed in DMD with no serious SE & nothing concerning so far which is extremely bullish - ⁠10 clinical sites in DMD in the US & overseas & more to open - ⁠minimum 20 pts will be dosed by year end - ⁠high interest from DMD families to enroll - ⁠20-30 pts screened & eligible for enrollment - ⁠on track to meet with FDA to discuss accelerated pathway ( high reward if they can produce the same results as what was released in feb 25) - ⁠FA clinical trials start in Q4 - ⁠CPVT clinical trials start in Q4 - ⁠strong cash runway thru 2027 - ⁠more than 25 agreements with some of the most prestigious institutions & universities for their Capsid Delivery method - ⁠with so much to come & strong progress in their clinical pipelines I believe price would appreciate 7.30s, 8.40s and 10.40 to come - ⁠I’m long for now unless thesis changes! - ⁠good luck plz DD!
1 · Reply
JazzyJ03
JazzyJ03 Aug. 13 at 9:08 PM
$SLDB (pleasantly surprised) >$7.37- >$8.43- >$10.37 Not trying to be greedy.
1 · Reply